Biogen to obtain licence for Ionis’ investigational SMA therapy
Biogen will handle the expenses associated with the development, production and potential marketing of BIIB115.
January 6, 2022
by Pharmaceutical-Technology
AstraZeneca, Ionis close deal on antisense therapy development
under the deal, AstraZeneca will manage the development and marketing of the antisense therapy globally.
December 30, 2021
by pharmaceutical-business-review
AstraZeneca and Ionis partner to develop antisense therapy eplontersen
AstraZeneca and Ionis Pharmaceuticals have signed an agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX.
December 9, 2021
by Pharmaceutical-Technology
Alzheimer’s treatment lowers tau by nearly 50 percent in Phase I trials
Biogen and Ionis announced positive topline data on investigational Alzheimer’s treatment, indicating 50 percent tau protein reduction.
July 30, 2021
by europeanpharmaceuticalreview
Ionis Appoints Clinical Development EVP
Eugene Schneider will oversee clinical development of novel antisense medicines across all of Ionis' therapeutic franchises.
January 11, 2021
by contractpharma
Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen
Ionis Pharmaceuticals and its wholly owned subsidiary Akcea Therapeutics, Inc., announced that Pfizer has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol ...
November 6, 2020
by pharmaceutical-business-review
Ionis Begins ALS Clinical Trial
Ionis Pharmaceuticals announced the first patients have been dosed with ION541 (also known as BIIB105), an investigational antisense medicine being developed as a potential therapy to treat most forms of amyotrophic lateral sclerosis (ALS) regardless ...
October 28, 2020
by americanpharmaceuticalreview
Ionis to Acquire Outstanding Shares of Akcea for $500M
Ionis will benefit from Akcea's pipeline and commercial products, and further strengthens financial position to support future investments.
September 1, 2020
by contractpharma
Akcea, Ionis Announce Initiation of Trial for Amyloid Cardiomyopathy Treatment
Akcea Therapeutics and Ionis Pharmaceuticals announced the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy).
January 16, 2020
by americanpharmaceuticalreview
Empirico, Ionis collaborate to develop antisense oligonucleotide therapeutics
Empirico has entered into a $660m deal with Ionis Pharmaceuticals to develop novel antisense oligonucleotide therapeutics. Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine therapeutic targets for indicatio
January 14, 2020
by pharmaceutical-business-review
Aro Biotherapeutics signs licensing agreement worth up to $1.4bn
Aro Biotherapeutics, a biotech firm engaged in the development of protein biologics called Centyrins, has signed a licencing deal that can potentially generate up to $1.4bn for the company.
January 13, 2020
by pharmaceutical-technology
Ionis Licenses Investigational Alzheimer's Therapy
Ionis Pharmaceuticals announced Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively reduce production ...
December 23, 2019
by americanpharmaceuticalreview